Technical Analysis for ENTA - Enanta Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 93.44 2.73% 2.48
ENTA closed up 2.73 percent on Wednesday, May 22, 2019, on 1.35 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ENTA trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
BB Squeeze Ended Range Expansion 0.00%
Above Upper BB Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Bollinger Band Squeeze Range Contraction 2.73%

Older signals for ENTA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Chemistry Biotechnology Chemical Compounds Infection Infectious Disease Cyclopropanes Hepatitis C Pyrrolidines Hepatitis C Virus HCV Infection Ns3 Ns5a Viruses
Is ENTA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 127.77
52 Week Low 64.085
Average Volume 192,576
200-Day Moving Average 85.849
50-Day Moving Average 92.1324
20-Day Moving Average 88.8565
10-Day Moving Average 89.401
Average True Range 3.6932
ADX 17.61
+DI 27.0315
-DI 16.2085
Chandelier Exit (Long, 3 ATRs ) 83.4204
Chandelier Exit (Short, 3 ATRs ) 94.64959999999999
Upper Bollinger Band 93.2176
Lower Bollinger Band 84.4954
Percent B (%b) 1.03
BandWidth 9.816052
MACD Line 0.0615
MACD Signal Line -0.705
MACD Histogram 0.7665
Fundamentals Value
Market Cap 1.78 Billion
Num Shares 19.1 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -86.52
Price-to-Sales 23.12
Price-to-Book 3.52
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 100.22
Resistance 3 (R3) 99.53 96.59 99.09
Resistance 2 (R2) 96.59 94.86 96.93 98.71
Resistance 1 (R1) 95.01 93.79 95.80 95.70 98.34
Pivot Point 92.07 92.07 92.46 92.41 92.07
Support 1 (S1) 90.49 90.34 91.28 91.18 88.54
Support 2 (S2) 87.55 89.27 87.89 88.17
Support 3 (S3) 85.97 87.55 87.79
Support 4 (S4) 86.66